[1] World Health Organization, World Malaria Report 2020, World Health Organization, Geneva, Switzerland. https://apps.who.int/iris/rest/bitstreams/1321872/retrieve.
[2] Zawawi A, Alghanmi M, Alsaady I, Gattan H, Zakai H, Couper K. The impact of COVID-19 pandemic on malaria elimination. Parasite Epidemiol Control. 2020 Nov;11:e00187.https://doi.org/10.1016/j.parepi.2020.e00187.
[3] Rogerson SJ, Beeson JG, Laman M, Poespoprodjo JR, William T, Simpson JA et al. Identifying and combating the impacts of COVID-19 on malaria. BMC Medicine. 2020; 18:239.https://doi.org/10.1186/s12916-020-01710-x.
[4] Sherrard-Smith E, Hogan AB, Hamlet A, Watson OJ, Whittaker C, Winskill P et al. The potential public health consequences of COVID-19 on malaria in Africa. Nat Med. 2020;26:1411-1416. https://doi.org/10.1038/s41591-020-1025-y.
[5] World Health Organization, 2020. The potential impact of health service disruptions on the burden of malaria: a modelling analysis for countries in sub-Saharan Africa.
[6] Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J et al. Artemisinin resistance in Plasmodium falciparum malaria. New Engl J Med. 2009; 361:455-467. https://doi.org/10.1056/NEJMoa0808859.
[7] Leang R, Taylor WR, Bouth DM, Song L, Tarning J, Char MC et al. Evidence of Plasmodium falciparum Malaria Multidrug Resistance to Artemisinin and Piperaquine in Western Cambodia: Dihydroartemisinin-Piperaquine Open-Label Multicenter Clinical Assessment. Antimicrob Agents Chemother. 2015;59(8):4719-4726. https://doi.org/10.1128/AAC.00835-15.
[8] Noedl H, Se Y, Schaecher K, Smith BL, Socheat D, Fukuda M. Evidence of artemisinin-resistant malaria in western Cambodia. N Engl J Med 2008; 359:2619-2620. https://doi.org/10.1056/NEJMc0805011.
[9] Pushpakom S, Iorio F, Eyers PA, Escott KJ, Hopper S, Wells A, Doig A, Guilliams T, Latimer J, McNamee C, Norris A, Sanseau P, Cavalla D, Pirmohamed M. Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov. 2019;18(1):41-58. https://doi.org/ 10.1038/nrd.2018.168.
[10] Shanmugam A, Muralidharan N, Velmurugan D, Gromiha M. M. Therapeutic Targets and Computational Approaches on Drug Development for COVID-19. Curr Top Med Chem. 2020;20(24):2210-2220. https://doi.org/10.2174/1568026620666200710105507.
[11] Chhabria MT, Patel S, Modi P, Brahmkshatriya PK. Curr Top Med Chem. 2016;16:2841–2862. https://doi.org/ 10.2174/1568026616666160506130731.
[12] Rossignol JF, Cavier R. New Derivatives of 2-Benzamido 5-Nitrothiazoles. United States Patent No 3,950,351, April 13, 1976.
[13] Cavier R, Rossignol JF. Etude de diverses associations d’anthelminthiques chez la souris Rev Méd Vét. 1982 ;133:779-783.
[14] Aslam S, Musher DM Nitazoxanide: clinical studies of a broad-spectrum anti-infective agent. Future Microbiol. 2007;2:583–590. https://doi.org/10.2217/17460913.2.6.583.
[15] Dubreuil L, Houcke I, Mouton Y, Rossignol JF. In vitro evaluation of activities of nitazoxanide and tizoxanide against anaerobes and aerobic organisms. Antimicrob Agents Chemother. 1996 ;40(10): 2266-2270. https://doi.org/10.1128/AAC.40.10.2266
[16] Anderson V R, Curran MP. Nitazoxanide: a review of its use in the treatment of gastrointestinal infections . Drugs. 2007 ;67(13) :1947–1967.https://doi.org/ 10.2165/00003495-200767130-00015.
[17] Rossignol JF, Kabil SM, El-Gohary Y, Younis AM. Nitazoxanide in the treatment of amoebiasis. Trans R Soc Trop Med Hyg. 2007;101:1025-1031. https://doi.org/ 10.1016/j.trstmh.2007.04.001.
[18] Chero JC, Saito M, Bustos JA, Blanco EM, Gonzalvez G, García H et al. Hymenolepis nana infection: symptoms and response to nitazoxanide in field conditions. Trans R Soc Trop Med Hyg. 2007;101:203–205. https://doi.org/10.1016/j.trstmh.2006.04.004.
[19] Speich B, Ame SM, Ali SM, Alles R, et al. Efficacy and safety of nitazoxanide, albendazole, and nitazoxanide-albendazole against Trichuris trichiura infection: a randomized controlled trial. PLOS Negl Trop Dis 2012;6:e1685. https://doi.org/ 10.1371/journal.pntd.0001685.
[20] Rossignol JF, El-Gohary M. Nitazoxanide in the treatment of viral gastroenteritis: a randomized double-blind placebo-controlled clinical trial. Aliment Pharmacol Ther. 2006;24:1423–1430. https://doi.org/10.1111/j.1365-2036.2006.03128.x.
[21] Rossignol JF, Abou Zekry M, Hussein A, Santoro MG. Effect of nitazoxanide in treating rotavirus diarrhea: a randomized, double-blind, placebo-controlled trial. Lancet. 2006;368:124–129. https://doi.org/10.1016/s0140-6736(06)68852-1.
[22] Siddiq DM, Koo HL, Adachi JA, Viola GM. Norovirus gastroenteritis successfully treated with nitazoxanide. J Infection. 2011;63: 394–397. https://doi.org/10.1016/j.jinf.2011.08.002.
[23] Rossignol JF. Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus. J Infect Public Health. 2016;9(3):227-230. doi:10.1016/j.jiph.2016. 04.001.
[24] Rossignol JF, Elfert A, Keeffe EB. Treatment of chronic hepatitis C using a 4-week lead-in with nitazoxanide before peginterferon plus nitazoxanide. J Clin Gastroenterol. 2010;44:504–509. https://doi.org/10.1097/mcg.0b013e3181bf9b15.
[25] Korba, B E, Montero, A B, Farrar, K, Gaye, K et al. Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication. Antiviral Research. 2008;77(1):56-63. https://doi.org/10.1016/j.antiviral.2007.08.005.
[26] Rossignol, JF. Nitazoxanide: A first-in-class broad-spectrum antiviral agent. Antiviral Research. 2014;110:94–103. https://doi.org/10.1016/j.antiviral.2014.07.014.
[27] Hoffman PS, Sisson G, Croxen MA, Welch K, et al. Antiparasitic drug nitazoxanide inhibits the pyruvate oxidoreductases of Helicobacter pylori, selected anaerobic bacteria and parasites, and Campylobacter jejuni. Antimicrobial agents and chemotherapy. 2007;51(3):868–876. https://doi.org/10.1128/aac.01159-06.
[28] Elazar M, Liu M, McKenna SA, Liu P et al. The Anti- Hepatitis C Agent Nitazoxanide Induces Phosphorylation of Eukaryotic Initiation Factor 2α Via Protein Kinase Activated by Double-Stranded RNA Activation. Gastroenterology. 2009;137(5):1827–1835. https://doi.org/10.1053/j.gastro.2009.07.056.
[29] Rossignol JF, La Frazia S, Chiappa L, Ciucci A, Santoro MG. Thiazolides, a New Class of Anti-influenza Molecules Targeting Viral Hemagglutinin at the Post- translational Level. Journal of Biological Chemistry. 2009;284(43):29798–29808. https://doi.org/10.1074/jbc.m109.029470.
[30] Stachulski AV, Santoro MG, Piacentini S, Belardo G et al. Second-generation nitazoxanide derivatives: thiazolides are effective inhibitors of the influenza A virus. Future Medicinal Chemistry. 2018;10(8):851–862. https://doi.org/10.4155/fmc-2017-0217.
[31] Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269-271. doi:10.1038/s41422-020-0282-0.
[32] Jasenosky LD, Cadena C, Mire CE, et al. The FDA-Approved Oral Drug Nitazoxanide Amplifies Host Antiviral Responses and Inhibits Ebola Virus. iScience. 2019;19:1279‐1290. https://doi.org/10.1016/j.isci.2019.07.003.
[33] Navarrete-Vazquez G, Chávez-Silva F, Argotte-Ramos R, Rodríguez-Gutiérrez MC et al. Synthesis of benzologues of Nitazoxanide and Tizoxanide: A comparative study of their in vitro broad-spectrum antiprotozoal activity. Bioorg Med Chem Lett. 2011;21:3168–3171. https://doi.org/10.1016/j.bmcl.2011.02.100.
[34] Karade HN, Acharya BN, Sathe M, Kaushik MP. Design, synthesis, and antimalarial evaluation of thiazole-derived amino acids. Med Chem Res. 2008;17:19–29. https://doi.org/10.1007/s00044-008-9089-0.
[35] Cabrera DG, Douelle F, Feng T-S et al. Novel Orally Active Antimalarial Thiazoles. J Med Chem. 2011;54:7713–7719. https://doi.org/10.1021/jm201108k.
[36] Sharma M, Prasher P. An epigrammatic status of the ‘azole’-based antimalarial drugs. RSC Med Chem. 2020;11:184-211. https://doi.org/10.1039/C9MD00479C
[37] Peña S, Scarone L, Medeiros A, Manta E, et al. Synthesis of precursors and macrocycle analogs of aerucyclamides as anti-trypanosomal agents. Med Chem Commun. 2012;3:1443-1448. https://doi.org/10.1039/C2MD20218B.
[38] Peña S, Scarone L, Manta E, Serra G. First total synthesis of aerucyclamide B. Tetrahedron Letters. 2013;54:2806–2808. https://doi.org/10.1016/j.tetlet.2013.03.060.
[39] Peña S, Fagundez C, Medeiros A, Comini M et al. Synthesis of cyclohexapeptides as antimalarial and anti-trypanosomal agents. Med Chem Commun. 2014;5:1309- 1316. https://doi.org/10.1039/C4MD00135D.
[40] Peña S, Scarone L, Serra G. Macrocycles as potential therapeutic agents in neglected diseases. Future Med Chem. 2015;7(3):355 -382. https://doi.org/10.4155/fmc.14.133.
[41] Franco J, Medeiros A, Benítez D, Perelmuter K, et al. In vitro activity and mode of action of distamycin analogues against African trypanosomes. Eur J Med Chem. 2017;126:776-788. https://doi.org/10.1016/j.ejmech.2016.12.002.
[42] Fagundez C, Sellanes D, Serra G. Synthesis of Cyclic Peptides as Potential Anti-Malarials. ACS Combinatorial Sci. 2018;20(4):212-219. https://doi.org/10.1021/acscombsci.7b00154.
[44] Posada L, Serra G. First total synthesis of versicotide D and analogs. Tetrahedron Lett. 2019;60(48):151281. http://doi.org/10.1016/j.tetlet.2019.151281.
[44] Fagundez C, Sellanes D, Peña S, Scarone L, et al. Synthesis, profiling, and in vivo evaluation of cyclopeptides containing N-methyl amino acids as antiplasmodial agents. ACS Med Chem Lett. 2019;10:137-141. https://doi.org/10.1021/acsmedchemlett.8b00543.
[45] Franco J, Scarone L, Comini MA. Novel distamycin analogues that block the cell cycle of African trypanosomes with high selectivity and potency. Eur J Med Chem. 2020;189:112043. https://doi.org/10.1016/j.ejmech.2020.112043.
[46] Serra G, Posada L, Hojo H. On-resin synthesis of cyclic peptides via tandem N-to-S acyl migration and intramolecular thiol additive-free native chemical ligation. Chem Comm. 2020;56(6):956-959. https://doi.org/10.1039/C9CC07783A.
[47] Alvarez N, Velluti F, Guidali F, Serra G et al. New BI and TRI-Thiazole copper (II) complexes in the search of new cytotoxic drugs against breast cancer cells. Inorg Chim Acta. 2020;508:119622. https://doi.org/10.1016/j.ica.2020.119622.
[48] Hohmann K, Mohr R, Hahnke M. (1974). Process for preparing an azo compound from a 2- aminothiazole diazo component.United States Patent 4046752. Washington; DC: EE.UU. 1974.
[49] Dickey JB, Towne EB, Wright GF. Nitration of 2-aminothiazoles. J Org Chem. 1955;20(4):499-510. https://doi.org/10.1021/jo01122a013.
[50] Odingo J, Bailey MA, Files M, Early JV et al. In vitro evaluation of novel Nitazoxanide derivatives against Mycobacterium tuberculosis. ACS Omega. 2017;2:5873-5890. https://doi.org/10.1021/acsomega.7b00892.
[51] Gergely M, Kollar L. Aminothiazoles and aminothiadiazoles as nucleophiles in aminocarbonylation of iodobenzene derivatives. Tetrahedron. 2018;74:2030-2040. https://doi.org/10.1016/j.tet.2018.03.007.
[52] Stachulski AV, Pidathala C, Row EC, Sharma R et al. Thiazolides as novel antiviral agents. 2. Inhibition of Hepatitis C virus replication. J Med Chem. 2011;54:8670-8680. https://doi.org/10.1021/jm201264t.
[53] Ballard TE, Wang X, Olekhnovich I, Koerner T et al. Synthesis and antimicrobial evaluation of Nitazoxanide-based analogues: identification of selective and broad spectrum activity. Chem Med Chem, 2010;6(2):362-377. https://dx.doi.org/10.1002%2Fcmdc.201000475.
[54] Posada L, Davyt D, Serra G. First total synthesis of versicotide A, B and C. RSC Adv. 2020;10:43653. https://doi.org/10.1039/D0RA09635K.
[55] Subirós-Funosas R, Prohens R, Barbas R et al. Oxyma: An efficient additive for peptide synthesis to replace the benzotriazole-based HOBt and HOAt with a lower risk of explosion. Chem Eur J. 2009;15:9394-9403. https://doi.org/10.1002/chem.200900614.
[56] Smilkstein M, Sriwilaijaroen N, Kelly JX et al. Simple and inexpensive fluorescence-based technique for high-throughput antimalarial drug screening. Antimicrob Agents Chemother. 2004;48:1803-1806. https://doi.org/10.1128/aac.48.5.1803-1806.2004.
[57] Gardner MJ, Hall N, Fung E, White O et al. Genome sequence of the human malaria parasite Plasmodium falciparum. Nature. 2002;419:498–511. https://doi.org/10.1038/nature01097
[58] Hall N, Karras M, Raine JD, Carlton JM et alA comprehensive survey of the Plasmodium life cycle by genomic, transcriptomic, and proteomic analyses. Science (New York, N.Y.). 2005; 307: 82–86. https://doi.org/10.1126/science.1103717
[59] Frech C, Chen N. Genome comparison of human and non-human malaria parasites reveals species subset-specific genes potentially linked to human disease. PLoS computational biology, 2011;7:e1002320. https://doi.org/10.1371/journal.pcbi.1002320
[60] W.L.F. Armarego, C. Chai, Purification of Laboratory Chemicals, sixth ed., Butterworth-Heinemann, Elsevier Inc., 2009.